TRS003 Bevacizumab: A Phase 3, Multicenter, Randomized and Double-Blind Study to Assess the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab in Subjects With Advanced Nonsquamous NSCLC
Purpose of Study:
To demonstrate the biosimilarity, by means of investigator-determined ORR (RECIST V1.1) by week 19, of TRS003 and China-approved bevacizumab in combination with paclitaxel-carboplatin for patients with unresectable, locally, advanced, recurrent or metastatic nonsquamous NSCLC.
August 1, 2020 - November 30, 2021
BRCR medical center
Zhejiang Teruisi Pharmaceutical Inc.
Contact Phone: 561-447-0614